Allitia DiBernardo, MD

Global head of medical affairs-neurology, Janssen Pharmaceutical

Articles by Allitia DiBernardo, MD

Importance of Evaluating Real-World Populations in MS: Allitia DiBernardo, MD

February 27th 2021

The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.

Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD

ByAllitia DiBernardo, MD

February 25th 2021

The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.

Allitia DiBernardo, MD

Articles by Allitia DiBernardo, MD

Importance of Evaluating Real-World Populations in MS: Allitia DiBernardo, MD

Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy

Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni

FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology

Decision-Making in De-Escalating Therapy for Multiple Sclerosis

Reinforce Ocrelizumab’s Role Across the Full Spectrum of More Advanced Progressive MS: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath